5 9.2. Cash and cash equivalents €  millions 31.12.2021 31.12.2020 31.12.2019 Carrying amount Acquisition cost Carrying amount Acquisition cost Carrying amount Acquisition cost Marketable securities 513.2 513.3 3,739.9 3,743.5 3,042.4 3,044.6 Bank accounts and other cash and cash equivalents 2,200.6 2,201.6 2,666.0 2,680.5 2,243.6 2,243.6 TOTAL 2,713.8 2,714.9 6,405.9 6,424.0 5,286.0 5,288.2 Marketable securities consist mainly of SICAV money-market funds and unit trusts (on which the return is based on EONIA). They are considered as financial assets at fair value through profit or loss. Term accounts with a maturity of less than three months at inception are shown on the Bank accounts and other cash and cash equivalents line. 9.3. Non-current financial assets € millions 31.12.2021 31.12.2020 31.12.2019 Carrying amount Acquisition cost Carrying amount Acquisition cost Carrying amount Acquisition cost Investmen ts in non-consolidated companies Sanofi (1) 10,472.6 4,033.5 9,304.5 4,033.5 10,595.5 4,033.5 Other listed securities (2) 34.5 20.6 30.7 12.0 5.8 9.8 Unlisted securities (3) 277.9 336.4 154.4 244.7 89.1 179.4 Financial assets at amortised cost Non-current loans and receivables 135.2 137.2 115.1 117.1 129.0 131.4 TOTAL 10,920.2 4,527.7 9,604.8 4,407.3 10,819.4 4,354.1 (1) L’Oréal’s stake in Sanofi was 9.36% at 31 December 2021. The carrying amounts at 31 December 2021, 31 December 2020 and 31 December 2019 (€10,472.6 million, €9,304.5  million and €10,595.5 million (respectively) correspond to the market value of the shares based on the closing price at each of these dates (€88.58, €78.70 and  €89.62, respectively). The acquisition cost of €4,033.5  million corresponds to an entry cost of €34.12. The investment is measured at fair value through other comprehensive income. (2) This heading includes listed securities of biotechnology start-ups. (3) This heading mainly includes: - strategic investments in investment funds measured at fair value through other comprehensive income including 50 million subscribed over 2020 in the L'Oréal fund for the regeneration of nature; - securities of our subsidiaries in Venezuela deconsolidated since 31 December 2015, for €94.4 million fully written down. In the absence of specific events, their acquisition cost is deemed to be the best possible estimate of fair value. 9.4. Other financial income and expenses This item is broken down as follows: € millions 2021 2020 2019 Interest component of pension costs -10.1 -13.3 -12.3 Other financial income and expenses -30.1 -23.3 -3.7 TOTAL -40.2 -36.6 -16.0 L ’ ORÉAL I UNIVERS AL REGISTRATION DOCUMENT 2021 325 2021 CONSOLIDATED FINANCIAL STATEMENTS Notes to the consolidated financial statements